Navigation Links
K-V Pharmaceutical Secures Commitment for $85 Million Loan, Reaches Agreement with Senior Noteholders on Principal Terms of Plan of Reorganization
Date:12/12/2012

h of time the Company and its subsidiaries will operate under the Chapter 11 cases; (9) risks associated with third-party motions in the Chapter 11 cases, which may interfere with the ability of the Company and its subsidiaries to develop one or more plans of reorganization and consummate such plans once they are developed; (10) the potential adverse effects of the Chapter 11 proceedings on the Company's liquidity or results of operations; (11) the ability to execute the Company's business and restructuring plans; (12) increased legal costs related to the Company's bankruptcy filing and other litigation; (13) that its Class A Common Stock and Class B Common Stock will be, or will continue to be, traded on the OTCQB Marketplace and whether sufficient volumes and liquidity will develop; and (14) the ability of the Company and its subsidiaries to maintain contracts that are critical to their operation, including to obtain and maintain normal terms with their vendors, customers and service providers and to retain key executives, managers and employees.

This discussion is not exhaustive, but is designed to highlight important factors that may impact our forward-looking statements.

Because the factors referred to above, as well as the statements included in Part I, Item 1A—"Risk Factors," of our Annual Report on Form 10-K for the fiscal year ended March 31, 2012 and under the heading "Risk Factors" in our Registration Statement on Form S-1 filed with the Securities and Exchange Commission on July 31, 2012, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. All forward-looking statements attributable to us are expressly qualified in their entirety by the cautionary statements in this "Cautionary Note Regarding Forward-Looking Statements" and the risk factors that are included under Part I,
'/>"/>

SOURCE K-V Pharmaceutical Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness
3. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
4. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
5. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
6. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
7. The respective roles of the public and private sectors in pharmaceutical innovation
8. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
11. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... , June 3, 2015  HireLifeScience.com, the ... industries, will host its 6 th annual ... Center at Raritan Center in Edison, ... sponsors include Novo Nordisk, Covance, Actavis and AstraZeneca.  ... will be exhibiting are Johnson & Johnson, MedImmune, ...
(Date:6/3/2015)... and CAMBRIDGE, Mass. and REYKJAVIK, Iceland ... a precision medicine company using the genome to improve ... by Genomics England (GeL) to provide clinical ... disease and cancer patients as part of the first ... UK National Health Service (NHS). WuXi ...
(Date:6/3/2015)... GEA's Panther™ NS3006L is a ... fully-equipped laboratory unit that is designed for continuous operation ... plants. The Panther™ NS3006L achieves the same results as ... easy installation with simple operation, quick maintenance and is ... used in many different industries, such as food, dairy, ...
(Date:6/2/2015)... , June 2, 2015 /CNW/ - Shell today celebrated ... in the premium category with an exhibit the size ... that included interactive demonstrations for media and the public, ... Shell V-Power NiTRO+ Premium Gasoline provides the best total ... engine performance: engine wear, gunk and corrosion. ...
Breaking Biology Technology:AstraZeneca Added as Sponsor for Industry Leading Life Science Hiring Event 2WuXi NextCODE Wins Genomics England Clinical Interpretation Tender in both Rare Disease and Cancer 2GEA Announces the Panther™ NS3006L, a Self-Contained, Fully-Equipped Laboratory Homogenizer Well Suited for Pilot Plants 2New Shell V-Power NiTRO+ Premium Gasoline Introduces Breakthrough Formulation for BEST TOTAL Engine Protection 2New Shell V-Power NiTRO+ Premium Gasoline Introduces Breakthrough Formulation for BEST TOTAL Engine Protection 3New Shell V-Power NiTRO+ Premium Gasoline Introduces Breakthrough Formulation for BEST TOTAL Engine Protection 4
... This release is available in German . ... und Energie (HZB), in cooperation with colleagues from Oxford and ... have for the first time observed a nanoscale symmetry hidden ... a symmetry showing the same attributes as the golden ratio ...
... ... software (OSS) in clinical trial electronic data capture and clinical data management. , ... Waltham, MA (PRWEB) January ... trial software, will gather on March 22nd, 2010 in Bethesda, Maryland (USA) for the ...
... ... Products is pleased to announce a comprehensive line of Spectrum benchtop laboratory equipment that ... a complete line of mixers, vortexers, dry baths, mini centrifuges, hotplates & magnetic stirrers ... ...
Cached Biology Technology:Golden ratio discovered in a quantum world 2Golden ratio discovered in a quantum world 3OpenClinica Global Conference to Bring Together Global Community for Open Source Clinical Trials Software 2OpenClinica Global Conference to Bring Together Global Community for Open Source Clinical Trials Software 3OpenClinica Global Conference to Bring Together Global Community for Open Source Clinical Trials Software 4Spectrum Introduces New Line of Spectrum Branded Benchtop Laboratory Equipment 2
(Date:5/26/2015)... DUBLIN , May 26, 2015 ... has announced the addition of the "Saudi ... report to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... Saudi Arabia is projected to grow ... This high growth is attributed to the surging ...
(Date:5/21/2015)... The Sync Project™ , a global ... today announced a collaborative partnership with Berklee,s Institute ... on collaboration on original research, joint course development and ... collaboration, The Sync Project and BerkleeICE are exploring the ... the 2015-2016 academic year.  The course ...
(Date:5/19/2015)... 19, 2015 Research ... addition of the  "Genetic Testing Market Outlook ... http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic Testing ... of the current and future genetic testing ... their working principles and types are covered ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Global Genetic Testing Market Outlook 2018 2
... global carbon cycle, helping sequester significant amounts of carbon. ... that they discolor coastal waters and reduce the amount ... known as "red tide," the term "harmful algal blooms" ... of algal biomass can sometimes also turn the ocean ...
... of scientists studying genetic pathways that are mutated in ... forms of congenital heart disease including hypertrophic cardiomyopathy ... the leading cause of sudden death in children and ... and successfully treated HCM in the lab. ...
... Massachusetts Institute of Technology biologist Graham Walker leads a ... recreate the creativity and excitement of his research lab: ... MIT colleagues to identify new research questions in science ... Walker will talk about his experiences running a science ...
Cached Biology News:Brown tide culprit sequenced: Genome of the first of algal bloom species 2Brown tide culprit sequenced: Genome of the first of algal bloom species 3Brown tide culprit sequenced: Genome of the first of algal bloom species 4Cancer-related pathways reveal potential treatment target for congenital heart disease 2Cancer-related pathways reveal potential treatment target for congenital heart disease 3Plenary speech by HHMI professor highlights efforts of scientist-educators 2Plenary speech by HHMI professor highlights efforts of scientist-educators 3
Mouse monoclonal [DJR3] to DcR1 (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
Request Info...
Applications: Beadlyte® assay Stability: 2 years at 4°C (lyophilized) or 6 months at -20°C (rehydrated) ...
Human acetylcholine receptor (AChR)-alpha. Exhibits homogenous, high affinity,binding to the receptor. Binds weakly to a64-78. Inhibits binding of many,myasthenia gravis sera to human AChR....
Biology Products: